The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Vincent J. Picozzi
Research Funding - FibroGen
J. Marc Pipas
Research Funding - FibroGen
Albert Koong
Research Funding - FibroGen
Amato Giaccia
Consultant or Advisory Role - FibroGen; FibroGen
Nathan Bahary
Research Funding - FibroGen
Smitha S. Krishnamurthi
Research Funding - FibroGen
Charles D. Lopez
Research Funding - FibroGen
Peter J. O'Dwyer
Research Funding - FibroGen
Katharina Modelska
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Vanessa Poolman
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
James Chou
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Ming Zhong
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Seth Porter
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Tom Neff
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen
Frank Valone
Employment or Leadership Position - FibroGen
Stock Ownership - FibroGen